RT @philipcrobinson: Secukinumab in nr-axSpA, in a mostly biologic naive cohort was effective: ASAS40 response of ~42%,
Tweet Content
Secukinumab in nr-axSpA, in a mostly biologic naive cohort was effective: ASAS40 response of ~42%, data from the Phase III prevent trial Abstract OP0106 #EULAR2020 @rheumnow https://t.co/KATpGJs2y9 https://t.co/zeBFS2pMl0
Show on Archive Page
On
Display in Search Results
On